Expansion of Fine Chemical Sales Driven by Increased Overseas Demand for Pharmaceutical Applications
First written in FY2021-Q1. 7 of 17 entries say "Advanced", first in FY2023-Q2. Latest entry: FY2026.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Although product sales to some domestic markets declined, sales to overseas markets were on an upward trend, and net sales were ¥2.27 billion, up 5.6% year on year.」
Despite a decline in sales to some domestic markets, increased sales to overseas markets resulted in a 5.6% year-on-year increase in revenue for the Fine Chemicals segment. - 2026-04-30AdvancedEarnings
「Although product sales to some domestic markets declined, sales to overseas markets were on an upward trend, and net sales were ¥2.27 billion, up 5.6% year on year.」
The Company reported declining sales in some domestic markets alongside a rising trend in overseas sales and higher segment revenue. - FY2026-H1AdvancedAnnual report
「Although product sales to some domestic markets declined, sales to overseas markets were on an upward trend, and the Fine Chemicals segment reported net sales of ¥1.21 billion, up 7.6% year on year.」
In the Fine Chemicals segment, sales to some domestic markets declined, while sales to overseas markets were on an upward trend, resulting in a 7.6% year-on-year increase in segment net sales. - FY2024-Q3AdvancedAnnual report
「The Fine Chemicals segment benefited from the normalization of socioeconomic activity, with domestic product sales also showing signs of recovery. Net sales were ¥1.73 billion, up 9.0% year on year for the cumulative period of the same quarter.」
Domestic Fine Chemicals product sales continued to recover as socioeconomic activity normalized, resulting in a 9.0% year-on-year increase in revenue for the cumulative period of the same quarter. - FY2024-Q2AdvancedAnnual report
「As socioeconomic activity normalized, domestic product sales also recovered gradually, resulting in Fine Chemicals Division net sales of ¥1.18 billion, up ¥120 million, or 12.3%, from the same quarter of the previous year.」
The recovery in domestic sales of fine chemical products as socioeconomic activity normalized continued, resulting in a 12.3% year-on-year increase in sales. - FY2024-Q1RestatedAnnual report
「As socioeconomic activity normalized, domestic product sales also recovered gradually, resulting in Fine Chemicals Division net sales of ¥620 million, up ¥70 million, or 13.8%, from the same quarter of the previous year.」
The company reconfirms the recovery in domestic sales of fine chemical products as socioeconomic activity normalizes, a trend that has continued from the previous fiscal year. - FY2023AdvancedAnnual report
「Sales in the Fine Chemicals segment were ¥2,110 million, up 13.3% from the previous fiscal year, as domestic product sales recovered with the normalization of economic and social activity.」
The focus shifted from the previous fiscal year's sales growth driven by increased overseas demand for pharmaceutical applications to a recovery in domestic sales as socioeconomic activity normalized, resulting in higher annual sales. - FY2023-Q3Continued recovery in domestic salesAnnual report
「As socioeconomic activity normalized, domestic product sales recovered, resulting in Fine Chemicals Division net sales of ¥1.59 billion, up 14.2% from the same quarter of the previous year.」
The recovery in domestic product sales as socioeconomic activity normalized continued to drive higher sales, replacing the previous driver of sales growth, namely increased overseas demand for pharmaceutical applications. - FY2023-Q2AdvancedAnnual report
「As socioeconomic activity normalized, domestic product sales also recovered gradually, resulting in Fine Chemicals Division net sales of ¥1.05 billion, up ¥140 million, or 16.3%, from the same quarter of the previous year.」
The recovery in domestic product sales as socioeconomic activity normalized progressed from the decline in domestic demand for pharmaceutical applications that had continued from the previous fiscal year, resulting in a 16.3% year-on-year increase in sales. - FY2023-Q1Shift toward recovery in domestic demandAnnual report
「As socioeconomic activity normalized, domestic product sales also recovered gradually, resulting in Fine Chemicals Division net sales of ¥540 million, up ¥100 million, or 23.9%, from the same quarter of the previous year.」
The company shifted from the domestic decline in demand for pharmaceutical applications reported in the previous year to a gradual recovery in domestic product sales as socioeconomic activity normalized. - FY2022-Q3RestatedAnnual report
「In the Fine Chemicals segment, sales of products for pharmaceutical applications in Japan also recovered gradually as economic and social activity normalized, despite the impact of the renewed spread of COVID-19. As a result, sales were ¥1,390 million, compared with ¥1,410 million in the same quarter of the previous year.」
The decline in domestic demand for pharmaceutical applications caused by the renewed spread of COVID-19 infections and the resulting lower sales in the Fine Chemicals Division continued. - FY2022-Q2RestatedAnnual report
「The Fine Chemicals Division reported net sales of ¥900 million, compared with ¥950 million in the same quarter of the previous year, partly because domestic demand for pharmaceutical applications declined amid the renewed spread of COVID-19 infections.」
The decline in domestic demand for pharmaceutical applications and the resulting lower sales continued, reversing the previous year's sales expansion driven by higher overseas demand for pharmaceutical applications. - FY2022-Q1Shift to declining domestic demand for pharmaceutical applicationsAnnual report
「The Fine Chemicals Division reported net sales of ¥440 million, compared with ¥510 million in the same quarter of the previous year, partly because domestic demand for pharmaceutical applications declined amid the renewed spread of COVID-19 infections.」
The company shifted from the previous year's sales expansion driven by increased overseas demand for pharmaceutical applications to lower sales in the first quarter because of declining domestic demand for pharmaceutical applications. - FY2021RestatedAnnual report
「The Fine Chemicals Division benefited from increased overseas demand for pharmaceutical applications, resulting in higher domestic sales volume. Net sales were ¥1.86 billion, an increase of ¥7 million, or 0.4%, from the previous fiscal year.」
The increase in domestic sales volume driven by higher overseas demand for pharmaceutical applications continued to generate annual sales growth of 0.4%. - FY2021-Q3RestatedAnnual report
「The Fine Chemicals Division benefited from increased overseas demand for pharmaceutical applications, resulting in higher domestic sales volume. Net sales were ¥1.41 billion, an increase of ¥30 million, or 2.2%, from the same quarter of the previous year.」
The increase in domestic sales volume driven by higher overseas demand for pharmaceutical applications continued to generate 2.2% year-on-year sales growth in the Fine Chemicals Division. - FY2021-Q2RestatedAnnual report
「The Fine Chemicals Division benefited from increased overseas demand for pharmaceutical applications, resulting in higher domestic sales volume. Net sales were ¥950 million, an increase of ¥30 million, or 4.2%, from the same quarter of the previous year.」
The increase in domestic sales volume driven by higher overseas demand for pharmaceutical applications continued to generate 4.2% year-on-year sales growth in the Fine Chemicals Division. - FY2021-Q1First statedAnnual report
「(Fine Chemicals Division) The Fine Chemicals Division benefited from increased overseas demand for pharmaceutical applications, resulting in higher domestic sales volume. Net sales were ¥510 million, an increase of ¥60 million, or 13.8%, from the same quarter of the previous year.」
For the first time, the company states that increased overseas demand for pharmaceutical applications led to higher domestic sales volume and a 13.8% year-on-year increase in Fine Chemicals Division sales.